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Oxidative stressAbstract The objective of this study was to develop and characterize chitosan nanoparticles
(CSNPs) to increase efﬁcacy of pravastatin (PR) on erythrocytes redox status. CSNPs and PR
loaded CSNPs (PRCSNPs) were prepared by ionic gelation method. The particle size, zeta poten-
tial, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier-
transform infrared (FTIR) and X-ray diffraction (XRD) were used to investigate physicochemical
characters of the prepared nanoparticles. The present results revealed that CSNPs and PRCSNPs
have nanosize about 90 nm with spherical shape, positive zeta potential and prolonged PR release.
Moreover, DSC and FTIR indicated no chemical interactions between PR and CS. In vitro studies
revealed that, erythrocyte uptake of PR from PRCSNPs was higher than free PR solution. Incuba-
tion of erythrocytes in high cholesterol plasma, hypercholesterolemia (HC), increases membrane
cholesterol, erythrocyte hemolysis, oxidized glutathione (GSH), protein carbonyl (PCC), and
malondialdeyhe (MDA). However, HC signiﬁcantly decreases PR uptake by erythrocytes, superox-
ide dismutase (SOD), glutathione peroxidase (GPx) catalase (CAT) activities, reduced GSH and
nitrite levels compared to control. By contrast, treatment of HC with PR plus CS as free drug or1, Saudi
in vitro
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Please cite this article in press as: Harisa, G.
study. Arabian Journal of Chemistry (2015),nanostructure formula keeps the measured parameters at values near that of control. The effect of
CSNPs and PRCSNPs on redox status of erythrocytes was more prominent than free drugs. In con-
clusion, PRCSNPs are promising drug carrier to deliver PR into erythrocytes, moreover, PRCSNPs
possess promising characteristics with high biological safety for treatment of HC induced disruption
of redox homeostasis.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Under normal physiological conditions, erythrocytes have
ability to release cardioprotective agents such as nitric oxide
(NO), adenosine triphosphate (ATP) and scavenging reactive
oxygen species (ROS) (Minetti et al., 2007; Cortese-Krott
and Kelm, 2014). However, under pathological conditions,
erythrocytes become as a source of ROS and lose their cardio-
protective potential (Minetti et al., 2007; Eligini et al., 2013).
For example, in hypercholesterolemia (HC), cholesterol
crystallization in cell membrane is increased and this behavior
disrupts redox homeostasis (Mason et al., 2004; Uydu et al.,
2012; Tziakas et al., 2009). In such cases, erythrocytes lose
antioxidant power by decreasing activity of antioxidant
enzymes and decrease glutathione (GSH) content as major cel-
lular antioxidant defense (Minetti et al., 2007). Therefore, they
become enriched with oxidizable products of proteins, lipids
and glutathione and are called oxidized erythrocytes
(Oxi-Ery) (Minetti et al., 2007). Behavior of Oxi-Ery is similar
to oxidized lipoproteins, so that Oxi-Ery takes in macrophages
and triggers foam cells formation (Minetti et al., 2007; Lin
et al., 2008; Tziakas et al., 2010; van Zwieten et al., 2012).
Although most of research on HC deals with oxidized lipopro-
teins, few studies deal with Oxi-Ery (Franiak-Pietryga et al.,
2009). Therefore, further studies are required to address this
issue.
Statins are selective inhibitors of 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMG-CoA reductase), a rate-
limiting enzyme of the cholesterol biosynthetic pathway in
the liver (Petyaev, 2015). Moreover, statins elicit peripheral
effect through decreasing erythrocytes membrane cholesterol
as well as preserve redox homeostasis (Forsyth et al., 2012;
Uydu et al., 2012). Therefore, statins have many pleiotropic
effects and been used in prevention and treatment of many dis-
eases particularly cardiovascular disease. Several side effects
such myopathies, memory impairment, neuropathies, elevated
liver enzymes, general weakness and depression were reported
for patients receiving high doses of statins (Petyaev, 2015).
Statins bioavailability is low; this required increasing doses;
however, increase-statin dosing may worsen their side effects
during statin treatment (Petyaev, 2015). Therefore, further
studies are required to enhance statins bioavailability such as
novel formulation with vehicles that may increase statins efﬁ-
cacy (Anwar et al., 2011). It has been reported that chitosan
nanoparticles (CSNPs) enhance bioavailability statins after
oral administration (Anwar et al., 2011).
Nanocarriers-based drug deliveries are promising vehicle
for targeted delivery, increase bioavailability, prolong action
and increase cellular uptake of drug (Nam et al., 2009; Tao
et al., 2011). Chitosan (CS) nanoparticles are biocompatible,
biodegradable, drugs protection and innovative therapiesI. et al., Influence of pravastatin chitosa
http://dx.doi.org/10.1016/j.arabjc.2015(da Silva et al., 2015). Besides using of CS as drug delivery
vehicle, it has biological effect such as cholesterol lowering
and ROS scavenging effects (Tao et al., 2011). However, pres-
ence of free cationic group on CS induces binding with ery-
throcyte membranes, resulting in hemostasis, and rouleaux
formation (Fernandes et al., 2008; Tsao et al., 2011; Yuan
et al., 2011). Therefore, masking cationic groups reduces the
harmful effect of CS on erythrocyte membranes (Ziemba
et al., 2012). It was reported that, CSNPs prepared by ionic
gelation method have low cationic properties, yet it still has
cell binding capability (Nam et al., 2009; Tsao et al., 2011;
Fan et al., 2012). Moreover, CSNPs have good erythrocyte
compatibility, and act as potential vascular drug delivery sys-
tem (Fan et al., 2012). Despite several studies documented
the beneﬁcial effects of nanoparticles, their effect on biological
systems is still contradictory and further studies are required to
conﬁrm their beneﬁcial effect or cancel harmful effects
(Fro¨hlich, 2012; Narasimhan et al., 2014). In light of this, there
has been a great interest inﬂuence of CSNPs and nano-statin
on HC induced erythrocytes dysfunction.
Erythrocytes have been utilized as in vitro model to study
physiological and pathophysiological situations (Fernandes
et al., 2008). In particular, they are interest model to study
membrane-related phenomena to better understanding of dis-
ease mechanisms, identiﬁcation of new diagnostic and thera-
peutic approaches (Pasini et al., 2010). Despite several
studies investigated the effect of statins and CS as cholesterol
lowering agents, until now none of them addressed the effect
of their combination as free form or nano-formula on erythro-
cytes. In this study, beneﬁts of pravastatin (PR) and CS as
hypocholesterolemic combination were investigated using ery-
throcytes as a vitro cellular model. This was achieved through
preparation and characterization of CSNPs and PR loaded
chitosan nanoparticles (PRCSNPs), moreover, the effect of
these nanoparticles on HC induced erythrocytes cholesterol
inclusion, oxidative status and hemolysis were investigated in
comparison with free PR plus CS, an attempt to elucidate
PRCSNPs biocompatibility and investigate their effect on
erythrocyte redox status in HC situation.
2. Materials and methods
2.1. Materials and equipment
Pravastatin (PR) was purchased from Riyadh Pharma,
Riyadh, Saudi Arabia. Sodium tripolyphosphate (TPP) and
glacial acetic acid were obtained from BDH, UK. Low
molecular weight chitosan, water-soluble cholesterol,
tetraethoxypropane, GSH, glutathione oxidized (GSSG),
O-pthalaldehyde (OPT), N-ethyl maleimide (NEM), and
thiobarbituric acid (TBA) were obtained from Sigma–Aldrichn nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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Pravastatin nanoparticles and redox homeostasis 3(St. Louis, MO, USA). Trichloroacetic acid (TCA) was pur-
chased from (Merck Germany), 2,4-Dinitrophenylhydrazine
from (BDH Chemical Ltd Poole UK) and guanidine
hydrochloride fromWinlab UK. All other chemicals used were
of reagent grade. The following equipments used in this study
include Hettich EBA 20 Centrifuge (Germany), Ultra
Centrifuge (Beckman Coulter, Pasadena, CA), Genesys10S
UV–Vis spectrophotometer (USA) and Ultra Performance
Liquid Chromatography (UPLC). Moreover, Zetasizer Nano
ZS (Malvern Instruments, Malvern, UK), Wide-angle X-ray
diffractometer (XRD, Rigaku Ultima IV, Tokyo, Japan),
FT-IR spectrophotometer (FT-IR Nicolet-380, Thermo Fisher
Scientiﬁc, Madison, USA) and A JEOL JSM-6380 LA scan-
ning electron microscope (SEM) (Jeol Ltd., Tokyo, Japan)
were used in used in this study.
2.2. Preparation and characterization of CSNPs and PRCSNPs
CSNPs and PRCSNPs were prepared by ionic gelation method
using CS (3% w/w) and TPP (1% w/w) based on our previous
study (Harisa et al., 2015). Brieﬂy, TPP solution was added
dropwise to 0.5 w/v of acidic solution of CS under continuous
magnetic stirring at room temperature. CSNPs were formed
spontaneously by interaction between negative groups of
TPP and positively charged amino groups of CS. Then, CSNPs
were sonicated for 3 min in order to break any aggregations
and reduce particle size. The particle size, polydispersity index
(PDI) and zeta potential (ZP) of CSNPs were measured by
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK)
based on dynamic light scattering (DLS) technique. The
entrapment efﬁciency and drug loading were calculated after
centrifugation at 16,000 rpm for a period of 30 min and the
amount of PR in supernatants was determined using UPLC.
The CSNPs were freeze-dried and stored at 5 C; the surface
morphology of nanoparticles was investigated by SEM. The
possible chemical interaction and the physical state of
nanoparticles were determined by FTIR and X ray analysis,
respectively (Hamidi et al., 2011).
2.3. Experimental design
In this study blood sample was obtained from apparent
healthy, male volunteer aged 45 years. Inclusion criteria were
based on normal plasma total cholesterol (150 mg mg/dL);
however, exclusion criteria are physical inactivity, bad dietary
habit, smoking, obesity, diabetes and other diseases. Blood
sample (50 ml) was drawn by venipuncture into heparinized
test tubes. Plasma samples were separated by centrifugation
at 3000 rpm, and the buffy coat on top of cells was removed.
Next, erythrocytes were gently washed 3 times with an equal
volume of phosphate buffered saline (pH 7.5), following by
further centrifugation and supernatant was discarded and cells
were separated. Plasma samples were mixed with water-soluble
cholesterol hereafter referred to as cholesterol-enriched plasma
(HC) (550 mg/dL) (Kanakaraj and Singh, 1989). HC was
conﬁrmed by determination of cholesterol level using choles-
terol oxidase method by a commercially available kit (Randox
Laboratories, Crumlin, UK). Washed erythrocytes were
in vitro mixed with normal plasma (150 mg/dL) and HC
plasma (550 mg/dL) and treated with tested substances, as well
as classiﬁed into six groups as follows:Please cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015Group 1: washed erythrocytes were suspended in normoc-
holesterolemic plasma, referred as normal control (NC).
Group 2: washed erythrocytes were suspended in normal
plasma plus a combination of PR (90 lM) (Broncel et al.,
2007), and CS (1 mg/ml) (Fernandes et al., 2008), this group
referred as normal control treated with PR plus CS, (NC
+ PR+ CS group).
Group3: erythrocytes were suspended in HC plasma,
and referred as (HC group) (Kanakaraj and Singh,
1989).
Group 4: erythrocytes were suspended in HC and treated
with a combination of PR and CS, referred as HC treated
with PR plus CS (HC+ PR+ CS group).
Group 5: erythrocytes were suspended in HC and treated
with CSNPs (HC + CSNPs group) (Fan et al., 2012).
Group 6: erythrocytes were suspended in HC and treated
with PRCSNPs (HC + PRCSNPs group).
All groups were incubated at 37 C for 24 h, afterward sam-
ples were utilized by the following investigations. The protocol
for this study conformed to the guidelines of the Institutional
Ethical Committee.
2.3.1. Determination of PR erythrocytes uptake
Erythrocytes were incubated with normal plasma as normal
control (NC) groups and with HC plasma as (HC) groups.
Next the groups were treated with PR or with PRCSNPs as
following groups 1: NC + PR, groups 2: NC + PRCSNPs,
groups 3: HC + PR, and groups 4: HC + PRCSNPs, all
group were incubated for 24 h at 37 C. Then, uptake of PR
by erythrocytes from PR solution and PRCSNPs was deter-
mined by calculation of the difference between initial and ﬁnal
PR concentrations in plasma at the start of the experiment and
after 24 h incubation time with erythrocytes. PR was extracted
from plasma by methanol. The method was performed on
acquity UPLC system, acquity UPLC BEH C18 column
(2.1 mm  50 mm, 1.7 lm). The mobile phase was a mixture
of 0.25% formic acid in distilled water and acetonitrile
(65:35, v/v), with ﬂow rate of 0.5 mL/min and injection volume
was one lL. Photodiode array (PDA) detector was set to
acquire 3D data from 210 to 280 nm while the 2D channel
was recording at 237 nm, and the column temperature was
kept at 50 C while sample temperature was kept ambient.
Method was validated and found to be linear, selective, precise
and accurate as per FDA guidelines with low limit of detection
0.1 lg/mL and low limit of quantitation 0.5 lg/mL (Abdel-
Hamid et al., 2012).2.3.2. Determination of erythrocytes cholesterol inclusion
The cholesterol inclusion into erythrocyte was determined as
following. Erythrocytes were incubated with HC, after 24 h
incubation time, plasma samples were separated from erythro-
cytes, and initial and ﬁnal cholesterol levels were determined
by the cholesterol oxidase method using commercially avail-
able kits (Randox Laboratories, Crumlin, England). The per-
cent of cholesterol inclusion (CI) on erythrocytes was
calculated as follows.
CI% ¼ CH conc:Intial  CH conc:Final
CH conc:Intial
 100n nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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4 G.I. Harisa et al.2.3.3. Determination of erythrocytes membrane cholesterol
Erythrocytes membrane cholesterol was extracted from hemo-
lyzed cells using the procedure of Rose and Oklander (1965), in
which lipids are extracted from an aliquot of erythrocyte mem-
brane suspension with chloroform-isopropanol (7:11, v/v).
Cholesterol was measured using cholesterol oxidase method
using commercially available kits (Randox Laboratories,
Crumlin, England).
2.3.4. Determination of erythrocytes membrane phospholipids
Phospholipid contents were determined as inorganic phospho-
rus by the following, 2 ml of chloroform extract was transferred
to a clean Pyrex glass tube, and the solvent was completely
evaporated. After addition of 0.2 ml perchloric acid (70%),
the tubes were placed in a heating block at 180 C until the yel-
low color was disappeared. Subsequently, 1 ml of distilled
water, 150 ll of 2.5% (w/v) ammonium molybdate and 150 ll
of 10% (w/v) ascorbic acid were added. All tubes were kept in
boiling water for 5 min and the extent of the blue color was read
spectrophotometrically at 800 nm (Rouser et al., 1970).
2.3.5. Assay of erythrocyte antioxidant enzymes
Erythrocyte catalase (CAT) activity was determined in ery-
throcyte lysate using the OxiSelectTMcatalase activity assay (Cell
Biolabs, San Diego, CA, USA). The CAT degrades H2O2 to
water and molecular oxygen, and the amount of degraded
H2O2 is proportional to the enzyme activity. The color change
of the reaction mixture was measured spectrophotometrically
at 520 nm. The CAT activity was calculated using a calibration
curve.
Glutathione peroxidase (GPx) activity was measured in
hemolysate by commercial RANSELTM assay Kit (Randox
Laboratories, Crumlin, UK). The GPx activity was assessed
by measuring the decrease in absorbance at 340 nm.
SOD activity in the diluted lysate was measured using the
commercial RANSODTM assay (Randox Laboratories, Crum-
lin, UK). This method employs xanthine and xanthine oxidase
(XOD) to generate superoxide radicals which react with 2-(4-
iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride
to form a red formazan dye. The absorbance was determined
spectrophotometrically at a wavelength of 505 nm. The assay
procedures were performed following the manufacturer’s assay
procedure. CAT, GPx and SOD were expressed as U/g Hb.
Hemoglobin was measured in the whole blood sample by stan-
dard laboratory method.
2.3.6. Assay of erythrocyte glutathione
Reduced glutathione (GSH)/Oxidized glutathione (GSSG)
contents of erythrocytes were measured using the method of
Hissin and Hilf (1976), using O-phthalaldehyde (OPT), which
forms a ﬂuorescent derivative with GSH. Brieﬂy, 0.2 mL ery-
throcyte pellet was diluted with 0.8 mL distilled water and pro-
teins precipitated by addition of 1 mL of 10% trichloroacetic
acid (TCA). The supernatant was used for GSH and GSSG
assays. For GSH assay, 4 mL of reaction mixture consisted
of 3.25 mL phosphate–EDTA buffer (0.1 M, pH 8.0),
0.25 mL OPT (1 mg/mL methanol) and 0.5 mL supernatant.
The ﬂuorescence of the GSH-OPT adduct was measured after
15 min using excitation and emission wavelengths of 350 and
450 nm, respectively.Please cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015For GSSG assay, N-ethyl maleimide (NEM) was used to
inhibit the oxidation of GSH to GSSG during the estimation
procedures, allowing the formation of a stable complex with
GSH. After incubation of 0.5 mL of supernatant with
0.2 mL NEM (0.04 M) for 30 min, GSSG was measured using
the same steps as the GSH assay, but using 0.1 N NaOH as a
diluent instead of phosphate–EDTA buffer. The quantiﬁca-
tions of GSH and GSSG were calculated using standard
GSH and GSSG ﬂuorescence and expressed as lmol/g hemo-
globin. The ratio of GSSG and GSH was calculated by speciﬁc
values in the samples.
2.3.7. Assay of erythrocytes protein carbonyl
The total protein carbonyl content (PCC) was determined in
hemolysate as index of protein oxidation by a spectrophoto-
metric method as described by Levine et al. (1994). The pro-
teins were precipitated from hemolysate by addition of 10%
TCA. The precipitate was resuspended in 1.0 mL of 2 M
HCl for the blank control, or in 2 M HCl containing 2%
2,4-dinitrophenyl hydrazine for the test samples. After incuba-
tion for 1 h at 37 C, protein samples were washed with alco-
hol/ethyl acetate mixture and precipitated again by the
addition of 10% TCA. The precipitated protein was dissolved
in 6 M guanidine hydrochloride solution and the absorbance
was measured at 370 nm. The molar extinction coefﬁcient of
22  103 M1-cm1 was used for calculating the PCC level
and expressed as nM of carbonyls formed per mg protein.
The total protein content was determined according to
Lowry et al. (1951), using bovine serum albumin as standard.
2.3.8. Assay of erythrocytes malondialdehyde
The concentration of malondialdehyde (MDA) in hemolysate,
an index of lipid peroxidation, was determined spectrophoto-
metrically (Ohkawa et al., 1979). A mixture of 200 lL of 8%
sodium dodecyl sulfate, 200 lL of 0.9% thiobarbituric acid,
and 1.5 mL of 20% acetic acid was added to a 200 lL super-
natant of hemolysate and 1.9 mL of distilled water was used
to make the volume up to 4 mL. After boiling for 1 h, the mix-
ture was cooled and 5 mL of n-butanol and pyridine (15:1) solu-
tion was added. The mixture was centrifuged at 5000 rpm for
15 min and the absorbance was measured at 532 nm. MDA
levels were calculated using tetraethoxypropane as standard.
2.3.9. Assay of erythrocyte nitrite
Nitrite was determined as index for NO production, erythro-
cytes were hemolysed by addition of ice-cold distilled water,
and hemoglobin was precipitated by addition of cold ethanol
and chloroform. After vortex, the mixture was centrifuged at
10,000 rpm for 10 min Carvalho et al. (2004). Nitrite concen-
trations were determined with Griess reagent according to
the Griess Reagent Kit instructions (Cayman, Ann Arbor,
USA). Firstly, nitrate was reduced to nitrite by nitrate reduc-
tase as described by Green et al. (1982), and 300 hundred lL
of plasma was deproteinized by adding 600 lL of 75 mM
ZnSO4 solution. The mixture was stirred, and centrifuged at
10,000 rpm for 5 min at ambient temperature. Then 100 lL
of supernatants was added to 40 lL of nitrate reductase
(20 mU), 50 lL of FAD (5 mM), 10 lL of NADPH
(0.6 mM), and 250 lL of phosphate buffer (50 mM). The mix-
tures were incubated for 1 h at 37 C, and then 150 lL of then nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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Table 1 The composition and characterization of CSNPs and
PR loaded CSNPs (PRCSNPs).
Parameters CSNPs PRCSNPs
CS/TPP ratio 3:1 3:1
Particle size (nm) 86.11 ± 3.76 91.23 ± 5.21
Polydispersity index 0.245 ± 0.04 0.221 ± 0.02
Zeta potential (mV) 20.22 ± 3.35 17.21 ± 4.90
Entrapment eﬃciency (%) – 57.84 ± 2.45
Drug loading (%) – 23.61 ± 0.32
Drug release 48 h (%) – 78.12 ± 4.81
Results were represented as M± SD, (N= 3).
Pravastatin nanoparticles and redox homeostasis 5mixture was added to 450 lL of Griess reagent and incubated
in the dark place for 30 min at room temperature. Absorbance
was measured at 545 nm; the nitrite levels were calculated from
sodium nitrite standard curve and expressed in lM.
2.3.10. Assay of erythrocyte hemolysis
Osmotic fragility behavior of erythrocytes was determined as a
measure of membrane integrity by the method of Parpart et al.
(1947). The hemolysis percent regarding NaCl solution was
determined as following. Firstly, 25 ll of erythrocyte from all
studied groups was added to a series of 2.5 ml saline solutions
(0.0–0.9% of NaCl) in test tubes. After gentle mixing and
standing for 15 min at room temperature, the samples were
centrifuged at 1500 rpm for 5 min then; absorbance of released
hemoglobin was measured at 540 nm. Last, hemolysis was
calculated as a percent from complete hemolysed samples
represented as 100% hemolysis.
2.4. Statistical analysis
The statistical differences between groups were analyzed by
one way ANOVA followed by TUKEY Kramer multiple
comparison test, using GraphPad Prism Software v 5.01. The
values at P< 0.05 were chosen as statistically signiﬁcant.
3. Results
In the present study, PR loaded CSNPs were successfully
prepared by ionic gelation method at ratio 3:1 for CS and
TPP, respectively. The surface morphologies of CSNPs and
PRCSNPs were shown in Fig. 1A and B. It was observed that
nanoparticles were in spherical shape and their surfacesFigure 1 SEM images of plain CSNPs (A); PRCSNPs (B); particle si
ﬁgure represents the micrograph of CSNPs (A) and PRCSNPs (B) at o
had a narrow particle size distribution. The average of particle sizes wa
of CSNPs, however D displays PRCSNPs.
Please cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015appeared smooth with a narrow size of distribution. The pre-
pared CSNPs and PRCSNPs showed a unimodal size distribu-
tion (Fig. 1C and D), with nano size of 86.11 ± 3.76 and
91.23 ± 5.21 nm for CSNPs and PRCSNPs, respectively. A
PDI values for loaded and unloaded nanoparticles are less
than 0.3, which indicated homogeneity in particle size distribu-
tion. Moreover, both CSNPs and PRCSNPs exhibited a posi-
tive ZP. These results indicated that the nanoparticles were
prepared successfully in terms of morphology and the uniform
size distribution.
In addition, one of the signiﬁcant parameters to be consid-
ered in CSNPs formulations is to get sufﬁcient drug loading.
As seen in Table. 1, the entrapment efﬁciency and drug loading
of PR were 57.84 ± 2.45, and 23.61 ± 0.32 respectively. The
loading of drug was improved by nanoparticle formulation.
Regarding the nanoparticles stability, there were no detectable
changes in color, odor, or transparency. In addition, neither
CSNPs nor PRCSNPs did not show signiﬁcant change in theirze analysis of CSNPs (C) and PRCSNPs (D). Bar = 100 nm. This
ptimal conditions. The nanoparticles showed a spherical shape and
s measured using dynamic light scattering (DLS). C displays DLS
n nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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Figure 4 XRD patterns of PR, CSNPs and PRCSNPs.
6 G.I. Harisa et al.particle size and PDI upon storage for 1 month at 4 C. In
order to evaluate whether the PR undergoes chemical or phys-
ical changes or not when it is prepared in nanoparticles formu-
lations, DSC, FTIR and XRD were examined. DSC was done
to see the thermal behavior and crystallinity of PR after load-
ing to CSNPs Fig. 2. DSC thermogram of PR showed a sharp
melting peak at 175 C. There were no thermal peaks for
PRCSNPs that are related to melting point of PR. This could
be attributed to the incorporation of PR in CS polymer matri-
ces of the obtained nanoparticles. Moreover, FTIR spec-
troscopy was used to study the chemical interaction between
PR and CS Fig. 3. The present results revealed the absence
of interactions between PR and CS. The physical state of the
materials was investigated by using XRD. The characteristic
XRD spectra of pure drug (PR) and PR loaded CSNPs are
presented in Fig. 4. The results of XRD experiment indicated
that there are no appearance peaks of PR crystals. These
results proved that PR had been added into the CS matrix in
amorphous. PR release from PRCSNPs in phosphate buffered
saline pH 7.4 at 37 C, showed a biphasic pattern with an ini-
tial burst drug release followed by sustained release up 48 h.Figure 2 Differential scanning calorimetry (DSC) of PR, CS,
CSNPS as well as PRCSNPs.
Figure 3 Fourier-transform infrared (FTIR) spectra of PR, CS,
TPP, CSNPs and PRCSNPs.
Please cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015The rapid PR releasing was mostly due to the nanoparticles
surface drugs, which could simply diffuse in the ﬁrst 6 h. The
slow release could be caused by the diffusion of the drug from
the CSNP matrix following by the degradation of the polymer
up 48 h. The experiments were achieved in triplicate. The
release of PR from PRCSNPs showed 78.12 ± 4.81% after
48 h (Table 1 and Fig. 5).
In the current work, the uptake of PR from PRCSNPs by
erythrocytes was signiﬁcantly higher than the uptake of free
PR (control). However, cellular uptake of PR from the control
and PRCSNPs was decreased in the presence of HC; these
results were annotated in Fig. 6. Moreover, incubation of ery-
throcytes with HC induced a signiﬁcant increase of cholesterol
loading into erythrocyte membrane as compared to control
ones (P 6 0.05.). On the other hand, treatment with PR plus
CS, CSNPs, or PRCSNPs signiﬁcantly decreased cholesterol
loading into erythrocyte membrane compared to HC group,
Fig. 7 displayed these results.Figure 5 In vitro releasing proﬁle of control PR and PRCSNPs
in phosphate buffered saline (PBS) of pH 7.4 at 37 C. Results
were represented as M± SD, (N= 3).
n nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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Figure 6 Cellular uptake of PR from free solution and CSNPs
by erythrocytes incubated with normal plasma and HC plasma.
One-way analysis of variance used for data analysis; Tukey
posttest used to determine the statistical differences between
groups. Results were represented as Mean ± SD, (N= 6). a,
signiﬁcant decrease from NC, b, signiﬁcant increase from NC and
HC incubated with free PR, c, signiﬁcant increase from incubated
with free PR. P 6 0.05.
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Figure 7 Effect of PR plus CS, CSNPs, and PRCSNPS on
percent of cholesterol inclusion into erythrocytes membrane
incubated with HC plasma compared to normal control. One-
way analysis of variance used for data analysis; Tukey posttest
used to determine the statistical differences between groups.
Results were represented as Mean ± SD, (N= 6). Superscript
letters indicated when signiﬁcant differences observed from either
control group or HC group. a; signiﬁcantly decrease from control,
b; signiﬁcantly increase from control, P 6 0.05.
Pravastatin nanoparticles and redox homeostasis 7The present results reveal that, exposure of erythrocytes to
HC induced a signiﬁcant increase of membrane cholesterol/
phospholipids ratio (CH/PL) and erythrocytes hemolysis
compared to control (P 6 0.05). However, incubation of ery-
throcytes with HC in the presence of PR plus CS, CSNPS,
or PRCSNPs preserved CH/PL ratio near and hemolysis that
of control ones. Table 2 displayed the effect of HC and tested
formulations on erythrocyte membrane CH/PL and hemolysis
percent.
Table 3 showed that, activity of SOD, GPx, CAT as well as
SOD/CAT and SOD/GPx ratios of control erythrocyte group
and incubated erythrocyte groups with PR plus CS as free drug
or as nanoparticle formulations. These data indicated that, the
treatment of erythrocytes with a combination of PR and CS
preserves activity of antioxidant enzymes and their ratios at
value near that of control one. However, a signiﬁcant
(P 6 0.05) decrease in SOD, GPx, and CAT activities was
observed in erythrocytes incubated with HC compared to
control. SOD/CAT and SOD/GPx ratios were signiﬁcantly
increased by exposure to HC plasma. On the other side, treat-
ment of HC group with a combination of PR plus CS, CSNPs,Please cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015or PRCSNPs ameliorates activity of measured enzymes and
their ratios compared to HC group. There is no signiﬁcant
difference between PR plus CS and PRCSNPs.
In the present results, GSH levels and GSH/GSSG ratio
markedly decreased in HC treated group compared to normal
control cells (P 6 0.05). However, GSSG, MDA and PCC
were signiﬁcantly increased by HC exposure compared to con-
trol cells (P 6 0.05). Treatment of HC group with free PR plus
CS or as nanoparticles kept GSH, GSSG, MDA and PCC at
values similar to control group. With respect to nitrite level,
HC exposure caused a signiﬁcant decrease of nitrite level
compared to the control (P 6 0.05). However, incubation of
erythrocytes with either free drugs or nanoparticles elicits
marked increase of nitrite level compared to HC treated cells
(P 6 0.05). The effect of CSNPs and PRCSNP on GSH,
GSSG, PCC, MDA and nitrite was pronounced (18–31%)
than free CS plus PR. Table 4 showed the statistical data
corresponding to these results.
4. Discussion
The integration of nanotechnology with biology has led to
development of drug nanocarriers that increase drug bioavail-
ability, enhance intracellular delivery, and sustained release of
drugs (Wang et al., 2014). Nanotechnology was applied to deli-
ver drugs to treat several chronic diseases (da Silva, 2015).
Despite Psarros et al. (2012) reported that nanotechnology
elicits beneﬁcial effect in treatment of vascular diseases, further
studies are required to conﬁrm this assumption.
In the present study, the prepared nanoparticles have
nanosize as well as good entrapment efﬁciency and drug
release. These observations concur with earlier studies, demon-
strated that statins could be prepared as nanoparticles with
acceptable physicochemical properties (Zhang et al., 2010;
Anwar et al., 2011; Tiwari and Pathak, 2011; Harisa et al.,
2015; da Silva et al., 2015). Herein, erythrocyte uptake of PR
from PRCSNPs was higher than free PR solution. This effect
may attribute to positive ZP of PRCSNPs that enhanced PR
entry into erythrocytes. These ﬁndings are in agreement with
several studies, reported that nanocarriers with positive ZP
interact with negatively charged cells membrane (Bankapur
et al., 2014). In addition, Alexis et al. (2008) indicated that pos-
itively charged nanocarriers have higher cellular uptake in
comparison with neutral or negatively charged one. Addition-
ally, passive transport may involve in nanocarriers uptake by
erythrocyte (Bankapur et al., 2014). CSNPs bind to negatively
charged cell membranes by an electrostatic interaction driven
by its positively charged amino group (da Silva, 2015).
In HC conditions, erythrocytes are ﬂoating in cholesterol
enriched medium, therefore free cholesterol molecules were
trapped in erythrocyte membrane (Franiak-Pietryga et al.,
2009). In this study, HC increased cholesterol inclusion on ery-
throcytes, and these results are in agreement with our previous
study and other studies (Harisa and Badran, 2015; Uydu et al.,
2012). In contrary, the treatment with PR plus CS or their
nanoparticles prevents the deposition of cholesterol into ery-
throcyte membranes. Similarly, Franiak-Pietryga et al. (2009)
and Foryth et al. (2012) reported that statins decrease choles-
terol content in erythrocyte membranes. Furthermore, Tsao
et al. (2011), indicated that CS and CSNPs elicit cholesterol-
lowering effect. The interaction between positively chargedn nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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Table 3 Effect of HC plasma with or without treatment on erythrocyte SOD, GPx and CAT and their ratios compared to control
erythrocytes.
Parameters NC NC+ PR+ CS HC HC+ PR+ CS* HC+ CSNPs HC+ PRCSNPs
SOD 1292 ± 98.6 1488 ± 184 945.5 ± 83.8a 1207 ± 98.6c 1130 ± 105c 1251 ± 1106c
GPx 47.17 ± 4.04 55.77 ± 6.39 21.99 ± 4.20a 41.10 ± 4.91c 31.10 ± 2.93c 45.10 ± 5.93c
CAT 72.80 ± 8.00 82.50 ± 7.22 31.58 ± 3.10a 70.1 ± 5.22c 57.56 ± 4.96c 71.37 ± 6.48c
SOD/GPx 27.39 ± 3.83 26.68 ± 2.35 43.1 ± 5.46b 28.36 ± 3.10d 36.33 ± 2.68d 28.53 ± 2.83d
SOD/CAT 17.75 ± 1.88 18.04 ± 1.72 29.94 ± 3.24b 17.22 ± 1.67d 19.63 ± 2.33d 16.83 ± 1.39d
One-way analysis of variance used for data analysis; Tukey’s posttest was used to determine the statistical differences between groups. Results
were represented as M± SD, (N= 6). Superscript letters indicated when signiﬁcant differences were observed from either control group or HC
group. a; signiﬁcantly decrease from control, b; signiﬁcantly increase from control, c; signiﬁcantly higher than HC, d; signiﬁcantly lower than
HC, P 6 0.05. Units; SOD, GPx and CAT were expressed as U/g Hb.
* Indicated that HC treated with free PR + CS as positive control compared to HC treated with PRCSNPs to show how using nanotech-
nology inﬂuences the biochemical measures.
Table 4 Effect of HC with or without tested agents on erythrocyte GSH, GSSG, GSH/GSSG ratio, MDA, PCC, and nitrite content
compared to control erythrocytes.
Parameters NC NC+ PR+ CS HC HC+ PR+ CS* HC+ CSNPs HC+ PRCSNPs
GSH 17.41 ± 2.28 21.05 ± 1.98 8.976 ± 1.76a 13.77 ± 1.58c 14.98 ± 1.67c 16.69 ± 1.43c
GSSG 0.418 ± 0.21 0.380±.08 0.883 ± 0.30b 0.510 ± 0.06c 0.622 ± 0.14d 0.415±.08d
GSH/GSSG 42.65 ± 4.23 55.39 ± 8.01 10.17 ± 1.12a 30.92 ± 3.41c 24.80 ± 2.75c 36.40 ± 4.11c
MDA 13.24 ± 1.11 10.45 ± 1.10 28.45 ± 1.89b 17.71 ± 1.73d 21.19 ± 2.27d 14.57 ± 1.37d
PCC 1.93 ± 0.34 1.23 ± 0.21 6.24 ± 0.84b 2.94±.0.55d 3.23 ± 0.64d 2.02 ± 0.61d
Nitrite 581.8 ± 97.14 620.1 ± 98.47 298.3 ± 34.56a 543.6 ± 91.77c 530.4 ± 67.43c 565.0 ± 77.65c
Data were analyzed using one-way analysis of variance followed by Turkey’s posttest to determine the statistical differences between groups.
Results were represented as mean ± SD, (N= 6). Superscript letters indicated when signiﬁcant differences observed from either control group
or HC group. a; signiﬁcantly decrease from control, b; signiﬁcantly increase from control, c; signiﬁcantly increase from HC group, d;
signiﬁcantly decreased from HC group, P 6 0.05. Units; GSH and GSSG expressed as lM/g Hb MDA, lM; PCO, nM mg/protein and nitrite,
lM.
* Indicated that HC treated with free PR + CS as positive control compared to HC treated with PRCSNPs to show how using nanotech-
nology inﬂuence the biochemical measures.
Table 2 Effect of HC plasma with or without treatment on erythrocytes membrane cholesterol (CH), phospholipids (PL), CH/PL
ratio and hemolysis percent compared to control group.
Parameters NC NC+ PR+ CS HC HC+ PR+ CS* HC+ CSNPs HC+ PRCSNPs
CH 415.0 ± 34.0 358.7 ± 42.3 593.3 ± 72.60a 368.8 ± 53.98b 387.8 ± 51.51b 372.7 ± 53.4b
PL 683.0 ± 103 681.5 ± 70.0 558.7 ± 112.6 575.0 ± 142.6 647.8 ± 102.9 674.0 ± 87.19
CH/PL 0.61 ± 0.03 0.53 ± 0.04 1.062±.41a 0.64 ± 0.09b 0.60 ± 0.14b 0.55 ± 0.06b
Hemolysis (%) 11.50 ± 1.12 5.45 ± 0.43 28.6 ± 3.71a 13.52 ± 0.97b 15.63 ± 1.63b 12.43 ± 1.34b
One-way analysis of variance used for data analysis; Tukey’s posttest was used to determine the statistical differences between groups. Results
were represented as M± SD, (N= 6). Superscript letters indicated when signiﬁcant differences were observed from either control group or HC
group. a; Signiﬁcantly increase from control, b; signiﬁcantly decrease from HC, P 6 0.05. Units; Erythrocyte cholesterol expressed as (lg/mg
protein), while phospholipids were expressed as inorganic phosphate (lg/mg protein).
* Indicated that HC treated with free PR + CS as positive control compared to HC treated with PRCSNPs to show how using nanotech-
nology inﬂuences the biochemical measures.
8 G.I. Harisa et al.amino groups of CS and cholesterol may be contributed to
cholesterol membrane inclusion (Xia et al., 2010). Therefore,
Free PR and Cs combination as well as PRCSNPs treatment
decreased cholesterol accumulation into an erythrocytes
membrane.
In this work, GSH content, SOD, GPx, and CAT activities
were decreasing by HC exposure; these ﬁndings conﬁrmed that
HC induced oxidative stress. Several studies demonstrated thatPlease cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015the exposure of erythrocytes to HC produced depletion of
antioxidant capacity (Devrim et al., 2008; Franiak-Pietryga
et al., 2009; Aydin et al., 2009; Uydu et al., 2012). However,
increase of SOD/CAT and SOD/GPx ratios, GSSG, PCO
and MDA in erythrocytes exposed to HC attributed to
enhancement ROS production that consumes antioxidant
systems (Devrim et al., 2008; Aydin et al., 2009; Uydu et al.,
2012; Ramı´rez-Zamora et al., 2013). Consequently, Oxi-Eryn nanoparticles on erythrocytes cholesterol and redox homeostasis: An in vitro
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Pravastatin nanoparticles and redox homeostasis 9is formed and rich with GSSG, oxidized lipids and proteins,
therefore they interact with macrophages to produce foam cells
that have a primary role in atherogenesis (Minetti et al., 2007;
Franiak-Pietryga et al., 2009).
By contrast, treatment of erythrocytes with PR plus CS as
free drug or in nanoparticles keeps the measured oxidative
stress variable at values near that of control. Similarly, many
studies demonstrated that statins and CS preserve antioxidant
systems and inhibit HC induced oxidation of biomolecules
(Franiak-Pietryga et al., 2009; Aydin et al., 2009; Uydu
et al., 2012; Anandan et al., 2012; Anandan et al., 2013). In
addition, Nasr et al. (2014), demonstrated that CSNPs have
more powerful antioxidant compared to free CS. Likewise
Wen et al. (2013) suggested that CSNPs are more effective
against oxidative stress as compared to free CS. Therefore,
CSNPs are promising drug carriers in antioxidant system
(Yadav et al., 2012; Du et al., 2014). Herein, CSNPs and
PRCSNPs treatment maintain antioxidant capacity of erythro-
cytes. This indicated that, construction of PR and CS in
nanoparticles form not abolishes hypocholesterolemic and
antioxidant activities. The insigniﬁcant difference between
PR plus CS and PRCSNPs on antioxidant enzyme may be
attributed to partial masking of CS amino or hydroxyl group
of PR or delaying release of CS and PR from nanoparticles.
Similarly, it has been demonstrated that nanoparticles and free
drug elicit similar or improved biological effect (Kwak et al.,
2015).
One of cardioprotective function of erythrocytes is regula-
tion of nitric oxide (NO) homeostasis, therefore, impairment
of erythrocytes NO production has been reported in cardiovas-
cular diseases (Eligini, 2013). Herein, HC induced a signiﬁcant
decrease of NO production compared to the control. This
attributes to HC impairs L-arginine active transport into cells
and enhances ROS formation; therefore, NO production was
decreased (Mason et al., 2004). In addition, Eligini et al.
(2013) demonstrated that oxidative stress impaired NO path-
way in erythrocytes. Moreover, Ramı´rez-Zamora et al.
(2013) reported that ROS inhibits NO production. Conversely,
the treatment of HC group with PR plus CS elicits marked
increase of NO compared to HC. These results are similar to
several studies, which reported that statins improve NO level
(Harisa et al., 2012; Li and Forstermann, 2013). Moreover,
Heeba et al. 2009 established that statins restore NO level. This
may be due to ability of statins to decrease cellular cholesterol
inclusion (Forsyth et al., 2012; Uydu et al., 2012). In addition,
CS signiﬁcantly increased NO levels (Ozcelik et al., 2014;
Zhang et al., 2014). Moreover, it has been demonstrated that
CSNPs enhance NO production (Pattani et al., 2009). This
may be attributed to the presence of amino groups on CS that
scavenges ROS.
The increase of cholesterol inclusion into erythrocytes
membrane ratio decreases the membrane ﬂuidity, and conse-
quently, increased erythrocyte hemolysis. The hemolytic prod-
ucts of erythrocytes such as cholesterol, iron and oxidized
hemoglobin are powerful damaging agents that increase risk
of vascular damage (Tziakas et al., 2010). In the present study,
the increase of erythrocyte hemolysis by HC exposures runs in
parallel with observations documented in several earlier stud-
ies (Uydu et al., 2012). However, PR plus CS as free drug or
in nanoparticle formulae decreased HC-induced erythrocytes
hemolysis. These observations concur with earlier studies,
which reported that statins are protective agents againstPlease cite this article in press as: Harisa, G.I. et al., Influence of pravastatin chitosa
study. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015erythrocyte hemolysis (Uydu et al., 2012; Harisa et al.,
2012). Moreover, Anandan et al. (2013) indicated that CS
has membrane-stabilizing property. Therefore, PR and CS
are protective agents against erythrocytes hemolysis. The
decrease of erythrocytes hemolysis by PRCSNPs indicated that
safety of CSNPs and PRCSNPs on biological systems.
5. Conclusion
In conclusion, the prepared PRCSNPs have desired nanopar-
ticle size, high entrapment efﬁciency and drug release. PR
and CS are effective combination for treatment of HC induced
erythrocytes cholesterol inclusion and disruption of redox
homeostasis. PRCSNPs have similar activities in terms of
cholesterol inclusion inhibition, decrease hemolysis and
restoration of antioxidant activity to that of PR plus CS. How-
ever, their effect was pronounced on GSH, GSSG, PCC, MDA
and nitrite. A relatively small sample size and lack of in vivo
studies were the limitations of this study. Further large-scale
in vivo studies are required to address this issue.
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